Jonathan C. Meltzer, Executive Vice President, Operations at Labcorp Holdings Inc., reported the sale of 87 shares of common stock on February 12, 2026, at a price of $290.42 per share, for aggregate proceeds of $25,266, according to the filing. The transaction took place while the healthcare services company was trading near its 52-week high of $293.72 and carrying a market capitalization of $23.41 billion.
The filings also show Meltzer sold 70 shares on February 11, 2026, for $289.89 per share, yielding $20,292. That sale was executed to cover tax obligations tied to equity compensation, as set out in the Form 4 disclosure. On the same day, Meltzer exercised 243 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock.
A recent Fair Value assessment indicates the stock appears fairly valued. Separately, Labcorp is reported to have achieved a Piotroski Score of 9, a metric that signals strong financial health under that scoring framework.
Investors will note that Labcorp is scheduled to report quarterly results on February 17, 2026, a date that sits just days after the insider activity recorded in the Form 4 filings.
Corporate developments and operational updates
Recent company initiatives include an expansion of Labcorp's molecular residual disease testing portfolio, intended to better detect cancer recurrence in breast, lung, and colon cancers. The expansion includes two tests named Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome, which are positioned to broaden the company's diagnostic capabilities.
In a transaction affecting its service lineup, NAMSA acquired Labcorp's early development medical device testing unit. That unit encompassed services such as biocompatibility and microbiological testing.
On the governance side, Labcorp appointed John H. Sampson, M.D., Ph.D., and Victor Bulto to its Board of Directors. Sampson joins with experience from roles at the University of Colorado Anschutz School of Medicine and Duke University Health System, while Bulto comes from his position as President of Novartis' U.S. operations.
Finally, the company announced a quarterly cash dividend of $0.72 per share, payable to stockholders in March 2026.
Context for market participants
The reported insider sales and the RSU exercise occurred at a time when the share price exhibited upward momentum by trading close to its annual peak. For shareholders and analysts focused on underwriting quality, funding mix, and payout policies, the declaration of a cash dividend and the composition of recent board appointments are notable items. The disclosed Piotroski Score of 9, indicating strong financial signals within that framework, may be of particular interest to credit and fundamental analysts assessing balance-sheet resilience.
Because the company is due to report results on February 17, 2026, stakeholders will be watching the upcoming release for confirmation of operational trends and financial metrics.